Attila Bérces, Omixon CEO and founder, shared his recent Prezi formatted presentation that shows how next generation sequencing can serve as a diagnostic platform with a special focus on our software solution,Omixon Target.
We hope you will enjoy this:
The prestigious channel, GenomeWeb, published an article about “Software Vendors Cautiously Optimistic as Illumina Readies BaseSpace App Store for Market” and mentions Omixon. An excerpt from the article:
Omixon, for instance, is developing an HLA genotyping application for identifying disease associations using whole-genome or whole-exome data as well as from targeted sequencing data, Attila Bérces, the company’s CEO, told BioInform.
You can access the full article here (GenomeWeb subscription is needed). We are always happy when our work gets some attention from the international research communities.
We are grateful for the many researchers and genetists who attended our workshop on August 23, 2012 at Harvard Medical School. Omixon’s CEO, Attila Berces, initiated the workshop with a presentation of how targeted analysis differs from whole genome analysis.
The participants were able to test Omixon Target during the workshop, and witness its speed and accuracy first hand. Users also enjoyed working with the Omixon browser and being able to effectively visualize large amounts of data.
We have been highlighting the need for clinical applications in next-generation sequencing and affordable diagnostics for years and that was one of the reasons to organize a workshop at the Joseph B. Martin Conference Center, Harvard Medical School on the 23rd of August between 2 PM and 6PM where you can learn how to carry out the most precise mutation analysis for common diagnostic gene targets.
The workshop is, of course, free and all participants are provided with a free 6-month Omixon license. Finally, if you are interested in using Omixon Target, we offer a special 90% discount at the workshop.
You can find all the details here as well as the registration form. Please register soon as only a few seats left!
